Carnelian Shift

Carnelian PMS | Equity | | PMS

IME's View on Carnelian Shift

Strategy

Focused on - Manufacturing & Technology Sector

Investment Fund

Carnelian Shift is a strategy aimed at identifying investment opportunities in manufacturing and technology. While Carnelian is a relatively young AMC, they are backed by experienced finance professionals albeit ones that lack a public track record of fund management and a good start to performance in the PMS.

Fund's Strategy View

Carnelian Shift is a long-only Mid & small-cap strategy, focused on investing in 2 key themes - manufacturing & technology. The focus is on mid & small-cap companies with existing core competencies, strong BS, governance and returns ratios.

Fund Performance

A lack of 5 yr trailing performance data from our identified reliable data sources, prevents us from having a clear performance rating on the fund.

IME's View on Carnelian PMS

View on AMC

Carnelian is a young firm in the Indian alternatives space with an impressive founding team from ex-senior investment team members of Edelweiss Securities. Vikas Khemani, the ex-CEO, and Manoj, the head of research, have strong research and investment business-building pedigrees. The investment philosophy and processes are well defined, combining quality growth investing (QGARP) with deep forensic diligence and thematic insights. Performance has been strong.

AMC's Pedigree

The firm is fully founder-owned and led by seasoned capital market professionals with backgrounds in institutional equities, forensic research, and business leadership.

AMC Team

Carnelian is founded by seasoned capital markets professionals with deep institutional experience. Vikas Khemani, former CEO of Edelweiss Securities, brings strategic leadership and decades of market insight. Manoj Bahety, a pioneer in forensic research, developed the acclaimed “Analysis Beyond Consensus” framework. Swati Khemani adds depth across equity research, sales, and business operations. Despite the lack of fund management experience in their prior roles, they have proven their ability to execute the stated investment philosophy well.

Investment Philosophy

Carnelian’s investment philosophy is its QGARP (Quality Growth at Reasonable Price) approach. The framework seeks to identify high-quality businesses with strong cash flows, clean governance, and sustainable moats, while ensuring valuations are reasonable relative to growth prospects. Their research process integrates thematic foresight, bottom-up stock picking, and a proprietary forensic filter called CLEAR—used to evaluate cash flows, liabilities, earnings quality, and corporate governance. Growth is captured through two lenses: “Magic” stocks that are entering accelerated earnings phases due to inflection points like capex completion or leadership change, and “Compounders” that deliver stable, long-duration returns.

Investment Strategy

Carnelian Shift is designed to find attractive opportunities in structural decadal shifts in manufacturing and tech evolution.

Carnelian employs a Concentrated QGARP portfolio - Quality Growth companies (Business & Management) at a Reasonable Price. The strategy aims to hold 20-25 stocks in the portfolio.

Investment Framework

  • Investing in good businesses: with traits such as profitable, robust cost leadership, opportunity and market size, free cash flow generation, the incremental return on capital, time test and easy to understand, and sustainable moat.
  • Great Management: evaluated based on integrity, modesty and capability, efficient capital allocation and a record of strong governance and risk management culture.
  • Favourable Risk Reward: upside potential with margin of safety (through business risk, balance sheet risk, and valuations)
  • Negative Screening: Avoid companies based on Aggressive accounting principles, High financial leverage, Low tax incidence, Management having misaligned objectives, Management with poor governance record and/or Management in hurry to create value.

Forensic Analysis based on CLEAR Framework

Carnelian’s forensic analysis involves a 2 step approach:

  1. Carnelian forensic check: An automated template screening last 10 years of historical data, highlighting potential minesweepers, which get rejected at this stage 
  2. Forensic deep dive:  CLEAR Framework  Their forensic team will deeply analyse the annual reports % financials which will be presented in a prescribed format to the investment committee. 
CLEAR Framework CLEAR framework based on: Cash Flows (sustainable cash flows vs reported cash flows), Liability Analysis (True debt vs reported debt, contingent liability & likely impact on future earnings), Earnings Quality (True economic profit vs reported profit, discretionary vs non-discretionary profit), Asset Quality (Core vs non-core assets), and related party transaction & governance issues.Any Stock that does not qualify this framework will be rejected by Investment Committee.

Trailing Performance

1yr3yr5yrSince Inception
Carnelian Shift-3.130.535.7
S&P BSE 500-6.614.720.3
Alpha over Broad Mkt BM3.515.815.4
Nifty Midcap 150-5.721.8
Alpha over Category BM2.68.7

Performance as of: 30-Sep-25 | Inception Date: 06-Oct-20 | Performance are post-fees, pre-taxes. Global funds denominated in USD or fund currency.

Investment team

Vikas Khemani | 4-star rated FM

Co-Founder | 30 yrs Experience | 8 yrs at current firm

Past Experience: President (Edelweiss Capital), AVP (ICICI Securities)

Vikas Khemani has over 2 decades of experience of which he spent 17 years incubating and building several businesses to leadership positions including Institutional Equities and Equity Research as a CEO at Edelweiss Securities. He is associated with several industry bodies and committees including the CII National Council on Corporate Governance, FICCI Capital Markets Committee, Executive Council of Bombay Management Association. Vikas Khemani comes with strong business acumen and a deep understanding of the capital markets along with strong relationships with Corporate India.

Manoj Bahety | 4-star rated FM

Co-Founder | 28 yrs Experience | 7 yrs at current firm

Past Experience: Managing Partner (Omniscient Capital Advisors), Deputy Head Research (Edelweiss Securities), Sr. Manager (Morgan Stanley), Manager (Reliance Industries)

Manoj Bahety is a CA and CFA Charter holder with 20 years of rich and diverse financial services with marquee institutions. Manoj spent 11 years at Edelweiss Securities as Dy. Head - Institutional Equity Research, Head - forensic, thematic & mid-cap research. He is known for his "Analysis Beyond Consensus" forensic research approach which helped in avoiding pitfalls and identifying several multi-bagger ideas.

Swati Khemani | 4-star rated FM

Partner | 24 yrs Experience | 7 yrs at current firm

Past Experience: Edelweiss

Swati Khemani one of the Partners at Carnelian AMC. She brings over 13 years of experience in the financial services industry, with her previous stints at Edelweiss and her own venture Newedge Consulting. She is a CA and did her graduations in BCom.

IME Capital Logo

IME Capital is a research-first investments firm. We aim to disrupt the wealth management industry, by shrinking the gap in investment insights between central research teams & RMs/Clients.

Disclaimer MF/PMS/AIF/Direct Equities are all subject to market risks. Please read the scheme information and other related documents carefully prior to investing. Past performance is not indicative of future returns. Please consider your specific investment requirements before choosing a fund or designing a portfolio that suits your needs. Market & other data on this site has been sourced from what are considered to be reliable sources. All views shared (product ratings, views on individual securities etc.) are the proprietary property of IME Capital and cannot be used in any form without explicit written consent. IME Capital Pvt. Ltd. makes no warranties or representations, express or implied, on products offered through the platform (and that of our partners) or on the correctness of data & views shared. It accepts no liability for any damages or losses, however caused, in connection with the use of, or on the reliance of its product or related services. Detailed Disclaimer | © 2021 All rights reserved | ARN No: ARN-182445